Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 28, 1998 - Issue 12
309
Views
90
CrossRef citations to date
0
Altmetric
Research Article

Molecular genetics of the human cytochrome P450 monooxygenase superfamily

, , &
Pages 1129-1165 | Published online: 22 Sep 2008

Reference

  • ADEDOYIN, A., PRAKASH, C., O'SHEA, D., BLAIR, J. A. and WILKINSON, G. R., 1994, Stereoselectice disposition of hexobarbital and its metabolites: relationship to the S-mephenyto in polymorphism in Caucasian and Chinese subjects. Pharmacogenetics, 4, 27–38.
  • ANDERSSON, T., REGARDH, C.-G., Lou, Y.-C., ZHANG, Y., DAHL, M. L. and BERTILSSON, L., 1992, Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics, 2, 25–31.
  • ANTILLA, S., VAINIO, H., HlETANEN, E. et al. 1992, Immunohistochemical detection of pulmonary cytochrome P4501A and metabolic activities associated with P4501A1 and P4501A2 isozymes in lung cancer patients. Environmental Health Perspectives, 98, 179–182.
  • AOYAMA, T., YAMANO S., WAXMAN, D. J., LAPENSON, D. P., MEYER, U. A., FISCHER, V., TYNDALE, R., INABA, T., KALOW, W., GELBOIN, H. V. and GONZALEZ, F. J., 1989, Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. Journal of Biological Chemistry, 264, 10388–10395.
  • AOYAMA, T., YAMANO S., GUZELIAN, P. S., GELBOIN, H. V. and GONZALEZ, F. J., 1990, Five of 12 forms of human hepatic cytochrome P450 metabolically activate aflatoxin Bl. Proceedings of the National Academy of Sciences, USA, 87, 9790–9793.
  • ARLOTTO, M. P., TRANT, J. M. and ESTABROOK, R. W., 1991, Measurement of steroid hydroxylation reactions by high performance liquid chromatography as identity of P450 identity and function. Methods in Enzymology, 206, 454–476.
  • BEAUNE, P. H., UMBENHAUER, D. R., BORK, R. W., LLOYD, R. S. and GUENGERICH, F. P., 1986, Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. Proceedings of the National Academy of Science, USA, 83, 8064–8068.
  • BELL, D. R., PLANT, N. J., RIDER, C. G., NA, L., BROWN, S., ATEITALLA, I., ACHARYA, S. K., DAVIES, M. H., ELIAS, E. and JENKINS, N. A., 1993, Species-specific induction of cytochrome P-450 4A RNAs: PCR cloning of partial guinea-pig, human and mouse CYP4a cDNAs. Biochemical Journal, 294, 173–180.
  • BENITEZ, J., BARQUERO, M. S., CORIA, F., MOLINA, J. A., JIMENEZ -JIMENEZ, F. J. and LADERO, J. M., 1993, Oxidative polymorphism of debrisoquine is not related to the risk of Alzheimers disease. Journal of the Neurological Sciences, 117, 8–11.
  • BERTILSSON, L., DAHL, M. L., SJOQVIST, F., ABERGWISTEDT, A., HUMBLE, M., JOHANSSON, I., LUNDQVIST E. and INGELMAN -SUNDBERG, M., 1993, Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet, 341, 63.
  • BERTILSSON, L., HENTHORN, T. K., SANZ, E., TYBRING, G., SAAvE, J. and VILLE'N, T., 1989, Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin but not debrisoquine hydroxylation phenotype. Clinical Pharmacology and Therapeutics, 45, 348–355.
  • BEYELER, C., DALY, AK., ARMSTRONG M., ASTBURY, C., BIRD, H. A. and IDLE, J. R., 1994, Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: Influence of drug therapy and disease activity. Journal of Rheumatology, 21, 1034–1039.
  • BOARD, P. G., 1981, Biochemical genetics of glutathione S-transferase in man. American Journal of Human Genetics, 33, 36–43.
  • BORK, R. W., MUTO, T., BEAUNE, P. H., SRIVASTAVA, P. K., LLOYD, R. S. and GUENGERICH, F. P., 1989, Characterisation of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. Journal of Biological Chemistry, 264, 910–919.
  • BOTTOF SEREE E., EL -KHYARI, S., DE SOUSA, G., MASSACRIER, A., PLACID', M., CAU, P., PELLET, W., RAHMANI, R. and BARRA, Y., 1994, Tissue specific expression and methylation of the human CYP2E1 gene. Biochemical Pharmacology, 48, 1095–1103.
  • BOUCHER, P. D., Ruco, R. J. and HINES, R. N., 1993, Specific nuclear protein binding to a negative regulatory element on the human CYP1A1 gene. Journal of Biological Chemistry, 268, 7384–7391.
  • BOUCHER, P. D. and HINES, R. N., 1995, In-vitro binding and functional studies comparing the human CYP1A1 negative regulatory element with the orthologius sequences from rodent genes. Carcinogenesis, 16, 383–392.
  • BURBACH, B., POLAND, A. and BRADFIELD, C. A., 1992, Cloning of the Ah-receptor cDNA reveals a distinct ligand-activated transcription factor. Proceedings of the National Academy of Sciences, USA, 89, 8185–8189.
  • BUTLER, M. A., LANG, N. P., YOUNG, J. F., CAPORASO, N. E., VINEIS, P., HAYES, R. B., TAITEL, C. H., MASSENGILL, J. P., LAWSEN, M. F. and KADLUBAR, F. F., 1992, Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmaco-genetics, 2, 116–127.
  • CAMUS, A. M., GENESTE 0., HONKAKOSKI, P., BEREZIAT, J. C., HENDERSON, C. J., WOLF, C. R., BARTSCH, H. and LANG, M. A., 1993, High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Molecular Carcinogenesis, 7, 268–275.
  • CARRIER, F., OWENS, R. A., NEBERT, D. W. and PUGO, A., 1992, Dioxin-dependent activation of murine CYP1A1 gene transcription requires protein kinase C-dependent phosphorylation. Molecular Cell Biology, 12, 1856–1863.
  • CHANG, T. K., WEBER, G. F., CRESPI, C. L. and WAXMAN, D. J., 1993, Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Research, 53, 5629–5637.
  • CHASE, M. B., BAEK, S. J., PURTELL, D. C., SCHWARTZ, S. and SHEN, R. F., 1993, Mapping of the human thromboxane synthase gene (TBAXS1 ) to chromosome 7q34-q35 by two color flourescence in situ hybridization. Genomics, 16, 771–773.
  • COLEMAN, T., ELLIS, S. W., MARTIN, I. J., LENNARD, M. S. and TUCKER, G. T., 1996, 1 -methyl-4 - phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4—implications for susceptibility to Parkinson's disease. Journal of Pharmacology and Experimental Therapeutics, 277, 685–690.
  • CRESPI, C. L., PENMA, B. W., LEAKEY, J. A., ARLOTTO, M. P., STARK, A., PARKINSON, A., TURNER, T., STEEVIEL, D. T., RUDO, K., DAVIES, R. L. and LANGENBACH, R., 1990, Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450HE1. Carcinogenesis, 8, 1293–1300.
  • CRESPI, C. L., PENMAN, B. W., GELBOIN, H. V. and GONZALEZ, F. J., 1991, A tobacco smoke-derived nitrosamine, 4-(methylnitrosamine)-1 -(3-pyridy)-1-butone (NNK), is activated by the poly-morphic human cytochrome P4502D6 (CYP2D6). Carcinogenesis, 12, 1197–1201.
  • CROFTS, F., COSMA, G. N., CURRIE, D., TAIOLI, E., TONIOLOP and GARTE, S. J., 1993, A novel CYP1A1 gene polymorphism in African Americans. Carcinogenesis, 14, 1729–1731.
  • CZERWINSKI, M., MCLEMORE, T. L., GELBOIN, H. V. and GONZALEZ, F. J., 1994, Quantification of CYP2B7, CYP4B1 and CYPOR messenger RNAs in normal human lung and lung tumors. Cancer Research, 54, 1085–1091.
  • CZERWINSKI, M., MCLEMORE, T. L., PHILPOT, R. M., NHAMBURO, P. T., NHAMBURO, P. T., KORZEKWA, K., GELBOIN, H. V. and GONZALEZ, F. J., 1991, Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism. Cancer Research, 51, 4636–4538.
  • DAHL, M. L., JOHANSSON, I., BERTILSSON, L., INGELMAN -SUNDBERG, M. and SJOQVIST, F., 1995, Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. Journal of Pharmacology and Experimental Therapeutics, 274, 516–520.
  • DALY, A. K., BROCKMULLER, J., BROLY, F., EICHELBAUM M., EVANS, W. E., GONZALEZ, F. J., HUANG, J. D., IDLE, J. R., INGELMAN -SIINDBERG, M., ISHIZAKI, T., JACQZAIGRAIN, E., MEYER, U. A., NEBERT, D. W., STEEN, V. M., WOLF, C. R. and ZANGER, U. M., 1996, Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 6, 193–201.
  • DE MORAIS, S. M. F., SCITWEIKL, H., BLAISDELL, J. and GOLDSTEIN, J. A., 1993, Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochemistry and Biophysics Research Communications, 194, 194–201.
  • DE MORAIS, S. M. F., WILKINSON, G. R., BLAISDELL, J., NAKAMURA, K., MEYER, U. A. and GOLDSTEIN, J. A., 1994a. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. Journal of Biological Chemistry, 269, 15419–15422.
  • DE MORAIS, S. M. F., WILKINSON, G. R., BLAISDELL, J., MEYER, U. A., NAKAMURA, K. and GOLDSTEIN, J. A., 1994b, Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Molecular Pharmacology, 46, 594–598.
  • DING, S., LAKE, B. G., FRIEDBERG, T. and WOLF, C. R., 1995, Expression and alternative splicing of the cytochrome P-450 CYP2A7. Biochemical Journal, 306, 161–166.
  • DISTELRATH, L. M. and GUENGERICH, F. P., 1984, Characterisation of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs using antibodies raised to the analogous rat enzyme. Proceedings of the National Academy of Sciences, USA, 81, 7348–7352.
  • DISTELRATH, K. M., REILLY, P. E. B., MARTIN, M. V., DAVIS, G. G., WILKINSON, G. R. and GUENGERICH, F. P., 1985, Purification and characterisation of the human liver cytochrome P-450 involved in debrisoquine 4-hydroxylation and phenacetin 0-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 260, 9057–9067.
  • EATON, D. L., GALLAGHER, E. P., BAMIVILER, T. K. and KUNZE, K. L., 1995, Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics, 5, 259–274.
  • EICHELBAUM, M., SPANNBRUCKER, N., STEINCKE, B. and DENGLER, H. J., 1979, Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. European Journal of Clinical Pharmacology, 16, 183–187.
  • ELLIS, S. W., HAYHURST, G. P., SMITH, G., LIGHTFOOT, T., WONG, M. M. S., SIMULA, A. P., ACKLAND, M. J., STERNBERG, M. J. E., LENNARD, M. S., TUCKER, G. T. and WOLF, C. R., 1995, Evidence that aspartic acid 301 is a critical substrate contract residue in the active site of cytochrome P450 CYP2D6. Journal of Biological Chemistry, 270, 29055–29058.
  • EMA, M., SOGAWA, K., WATANABE, N., CHUJOH, Y., MATSUSHITA, N., GOTOHO FUNAE Y. and FUJII - KURIYAMA, Y., 1994, cDNA cloning and structure of mouse putative Ah receptor. Biochemical Biophysical Research Communications, 184, 246–253.
  • EVANS, W. E., RELLING, M. V., RAHMAN, A., McLE0D, H. L., SCOTT, E. P. and LIN, J. S., 1993, Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug phenotype in Black Americans. Journal of Clinical Investigation, 91, 2150–2154.
  • FARIN, F. M. and OMIECINSKI, C. J., 1993, Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue. Journal of Toxicology and Environmental Health, 40, 317–335.
  • FARIN, F. M., POHLMAN, T. H. and OM1ECINSKI, C. J., 1994, Expression of cytochrome P450s and microsomal epoxide hydrolase in primary cultures of human umbilical vein endothelial cells. Toxicology and Applied Pharmacology, 124, 1–9.
  • FERNANDEZ -SALGUERO, P. and GONZALEZ, F. J., 1995, The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics, 5, S123—S128.
  • FERNANDEZ -SALGUERO, P., HOFFMAN, S. M. G., CHOLERTON, S., MOHRENWEISER, H., RAUNIO, H., RAUTIO, A., PELKONEN, 0., HUANG, J., EVANS, W. E., IDLE, J. R. and GONZALEZ, F. J., 1995, A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CY P2A6 alleles. American Journal of Human Genetics, 57, 651–660.
  • FERNANDEZ -SALGUERO, P., PINEAU, T., HILBERT, D. M., MCPHAIL, T., LEE, S. S. T., KIMURA, S., NEBERT, D. W., RUDIKOFF, S., WARD, J. M. and GONZALEZ, F. J., 1995, Immune-system impairment and hepatic-fibrosis in mice lacking the dioxin-binding Ah receptor. Science, 268, 722–726.
  • FORRESTER, L. M., HENDERSON, C. J., GLANCEY, M. J., BACK, D. J., PARK, B. K., BALL, S. E., KITTERINGHAM, N. R., MCLAREN, A. W., MILES, J. S., SKETT, P. and WOLF, C. R., 1992, Relative expression of cytochrome P450 isozymes in human liver and association with the metabolism of drugs and xenobiotics. Biochemical Journal, 281, 359–368.
  • FORRESTER, L. M., NEAL, G. E., JUDAH, D. J., GLANCEY, M. G. and WOLF, C. R., 1990, Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. Proceedings of the National Academy of Sciences, USA, 87, 8306–8310.
  • FREEMAN, J. E., STIRLING, D., RUSSELL, A. L. and WOLF, C. R., 1992, cDNA sequence, deduced amino acid sequence, predicted gene structure and chemical regulation of mouse Cyp2e1. Biochemical Journal, 281, 689–695.
  • FUKANAGA, B. N., PROBST, M. R., REISZ-PORSZASZ, S. and HANIUNSON, 0., 1995, Identification of functional domains of the aryl hydrocarbon receptor. Journal of Biological Chemistry, 270, 29270–29278.
  • FURUYA, H., MEYER, U. A., GELBOIN, H. V. and GONZALEZ, F. J., 1991, Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA. Molecular Pharmacology, 40, 375–382.
  • GAEDIGK, A., BLum, M., GAEDICK, R., EICHELBAUM, M. and MEYER, U. A., 1991, Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolisers of the debrisoquine/sparteine polymorphism. American Journal of Human Genetics, 48, 943–950.
  • GALLAGHER, E. P., WIENKERS, L. C., STAPLETON, P. L., KUNZE, K. L. and EATON, D. L., 1994, Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Research, 54, 101–108.
  • GED, C., UMBENHAUER, D. R., BELLEW, T. M., BORK, R. W., SRIVASTAVA, P. K., S HINRIKI, N., LLOYD, R. S. and GUENGERICH, F. P., 1988, Characterisation of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-Hydroxylase. Biochemistry, 27, 6929–6940.
  • GIBSON, G. G. and SKETT, P. (eds), 1994, Introduction to Drug Metabolism, 2nd edn (Glasgow: Blackie). GILHAM, D. E., CAIRNS, W., PA, M. J., MODI, S., POULSOM, R., ROBERTS, G. C. K. and WOLF, C. R., 1997, Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica, 27, 111–125.
  • GOLDSTEIN, J. A. and DE MORAIS, S. M. F., 1994, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4, 285–299.
  • GOLDSTEIN, J. A., FALETTO, M. B., ROMKES -SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. and GHANAYEM, B. I., 1994, Evidence that CYP2C19 is the major (s)-mephenytoin 4'-hydroxylase in humans. Biochemistry 33, 1743–1752.
  • GONZALEZ, F. J., SCHMID, B. J., UMENO, M., McBRIDE, O. W., HARDWICK, J. P., MEYER, U. A., GELBOIN, H. V. and IDLE, J. R., 1988, Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA, 7, 79–86.
  • GONZALEZ, F. J., 1990, The molecular biology of cytochrome P450s. Pharmacology Reviews, 40, 243-288. GOTOH, Q., 1992, Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. Journal of Biological Chemistry, 267, 83–90.
  • GOUGH, A. C., MILES, J. S., SPURR, N. K., Moss, J. E., GAEDIGK, A., EICHELBAUM, M. and WOLF, C. R., 1990, Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature, 347, 773–776.
  • GOUGH, A. C., SMITH, C. A. D., HOWELL, S. M., WOLF, C. R., BRYANT, S. P. and SPURR, N. K., 1992, Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization and linkage analysis. Genomics, 15, 430–432.
  • GRAY, I. C., NOBLE, C., MORESU, R., FORD, S. and SPURR, N. K., 1995, A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics, 28, 328–332.
  • GUENGERICH, F. P., 1991, Reactions and significance of cytochrome P450 enzymes. Journal of Biological Chemistry, 266, 10019–10022.
  • GUENGERICH, F. P., 1994, Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicology Letters, 70, 133–138.
  • GUENGERICH, F. P., MARTIN, M. V., BEAUNE, P. H., KREIVIERS, P., WOLFF, T. and WAXMAN, D. J., 1986a, Characterisation of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. journal of Biological Chemistry, 261, 5051–5060.
  • GUENGERICH, F. P., MULLER, E. D. and BLAIR, I. A., 1986b, Oxidation of quinidine by human liver cytochrome P-450. Molecular Pharmacology, 30, 287–295.
  • HAEHNER, B. D., GORSKI, J. C., VANDENBRANDEN, M., WRIGHTON, S. A., JANARDAN, S. K., WATKINS, P. B. and HALL, S. D., 1996, Bimodal distribution of renal cytochrome P450 3A activity in humans. Molecular Pharmacology, 50, 52–59.
  • HAKKOLA, J., PASANEN, M., HUKKANEN, J., PELKONEN, 0., MAENPAA, J., EDWARDS, R. J., BOOBIS, A. R. and RAUNIO, H., 1996, Expression of xenobiotic metabolising cytochrome P450 forms in human full term placenta. Biochemical Pharmacology, 51, 403–411.
  • HALL, A. J. and WILD, C. P., 1994, Epidemiology of aflatoxin-related disease. In D. L. Eaton and J. D. Groopman (eds), The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance (New York: Academic), pp. 233-258.
  • HASHIMOTO, H., TOIDE, K., KITAMURA, R., FUJITA, M., TAGAWA, S., ITOH, S. and KAMATAKI, T., 1993, Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. European journal of Biochemistry, 218, 585–595.
  • HAYASHI, S., WATANABE, J. and KAWAJIRI, K., 1991b, Genetic polymorphisms in the 5' flanking region change transcriptional region of the human cytochrome P450I1E1 gene. Journal of Biochemistry (Tokyo), 110, 559–565.
  • HAYASHI, S., WATANABE, J., NAKACHI, K., EGUCHI, H. and GOTOH, 0., 1994, Interindividual difference in expression of human Ah receptor and related P450 genes. Carcinogenesis, 15, 801–806.
  • HAYASHI, S. I., WATANABE, J., NAKACHI, K. and KAWAJIRI, K., 1991a, Genetic linkage of lung cancer associated Msp1 polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene. Journal of Biochemistry, 110, 407–411.
  • HAYES, C. L., SPINK, D. C., SPINK, B. C., CAOJQ, WALKER, N. J. and SUTTER, T. R., 1996,17-Beta-estradiol hydroxylation catalysed by human cytochrome P4501B1. Proceedings of the National Academy of Sciences, USA, 93, 9776–9781.
  • HILDEBRAND, C. E., GONZALEZ, F. J., MCBRIDE, 0. and NEBERT, D. W., 1985, Assignment of the human 2,3,7,8-tetrachlorodibenzo -p- dioxin-inducible cytochrome P1-450 gene to chromosome 15. Nucleic Acids Research, 13, 2009–2016.
  • HIRVONEN, A., HUSGAFVEL -PURSIAINEN, K., ANTILLA, S., KARJALAINEN, A., SORSA, M. and VAINIO, H., 1992, Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics, 2, 259–263.
  • HOFFMAN, S. M. G., FERNANDEZ -SALGUERO, P., GONZALEZ, F. J. and MOHRENWEISER, H. W., 1995, Organisation and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19. Journal of Molecular Evolution, 41, 894–900.
  • IBEANU, G. C. and GOLDSTEIN, J. A., 1995, Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry, 34, 8028–8036.
  • IKEYA, K., JAISWAL, A. K., OWENS, R. A., Jos, J. E., NEBERT, D. W. and KIMURA, S., 1989, Human CYP1A2: Sequence, gene structure, comparison with the mouse and rat orthologous gene and differences in liver 1A2 expression. Molecular Endocrinology, 3, 1399–1408.
  • INABA, T., JuRimA, M. and KALO W., 1986, Family studies of mephenytoin hydroxylation deficiency. American Journal of Human Genetics, 38, 768–772.
  • INGELMAN -SUNDBERG, M., 1996, Genetic polymorphism of human ethanol inducible CYP2E1: harmacokinetic and toxicological implications. Presented at the 11th International Symposium on Microsomes and Drug Oxidations, 21-24 July, Los Angeles, California.
  • INGELMAN -SUNDBERG, M. and JOHANSSON, I., 1995, The molecular genetics of the human drug metabolising cytochrome P450s. In G. M. Pacifici and G. N. Fracchia (eds), Advances in Drug Metabolism in Man (Luxembourg, European Commission), pp. 543-586.
  • IMAOKA, S., OGAWA H., KIMURA, S. and GONZALEZ, F. J., 1993, Complete cDNA sequence and cDNA directed expression of CYP4A11, a fatty acid omega hydroxylase expressed in human kidney. DNA Cell Biology, 12, 893–899.
  • ISSEMANN, I. and GREEN, S., 1990, Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 347, 645–650.
  • JAISWAL, A. K., GONZALEZ, F. J. and NEBERT, D. W., 1985, Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo(a)pyrene metabolism. Nucleic Acids Research, 13, 4503–4520.
  • JOHANSSON, I., LINDROS, K. 0., ERIKSSON, H. and INGELMAN -SUNDBERG, M., 1991, Transcriptional control of CYP2E1 in the perivenous liver region and during starvation. Biochemical Biophysical Research Communications, 173, 331–338.
  • JOHANSSON, I., LUNDQVIST, E., BERTILSSON, L., DAHL, M.-L., SJOQVIST, F. and INGELMAN -SUNDBERG M., 1993, Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proceedings of the National Academy of Sciences, USA, 90, 11825–11829.
  • KALOW, W. and BERTILSSON, L., 1994, Interethnic factors affecting drug response. Advances in Drug Research, 25, 1–53.
  • KALOW, W. and TANG, B. K., 1991, Use of caffeine metabolic ratios to explore CYP1A2 and xanthine oxidase activities. Clinical Pharmacology, 50, 508–519.
  • KAMINSKY, L. S., DE MORAIS, S. M. F., FALETTO, M. B., DUNBAR, D. A. and GOLDSTEIN, J. A., 1993, Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Molecular Pharmacology, 43, 234–239.
  • KAPITULNIK, J., POPPERS, P. J. and CONNEY, A. H., 1977, Comparative metabolism of benzo(a)pyrene and drugs in human liver. Clinical Pharmacology and Therapeutics, 21, 166–176.
  • KATO, S., OA, M., MATSUKURU, N., TOKUNAGA, A., TAJIRI, T., YOUNG KIM, D., TSURUTA, H., MATSUDA, N., YAMASHITA, K. and SHIELDS, P. G., 1995, Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case-control study of gastric cancer and liver disease. Pharmacogenetics, 5, 141–144.
  • KAWAJIRI, K., EGUCHI, H., NAKACJI, K., SEKIYA, T. and YAMAMOTO, M., 1996, Association of CYP1A1 germ line polymorphism with mutations of the p53 gene in lung cancer. Cancer Research, 56, 72–76.
  • KAWAJIRI, K., NAKACHI, K., ItsTAI, K. et al., 1990, Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Letters, 263, 131–133.
  • KAWAJIRI, K., WATANABE, J., GOTOH, 0., TAGASHIRA, Y., SOGAWA, K. and FUJII -KURIYAMA, Y., 1986, Structure and drug inducibility of the human cytochrome P-450c gene. European Journal of Biochemistry, 159, 219–225.
  • KAWASHIMA, H., KUSUNOSE, E., KUBOTA, I., MAEKAWA, M. and KUSENOSE, M., 1992, Purification and NH2-terminal amino acid sequences of human and rat kidney fatty acid co-hydroxylases. Biochemka Biophyska Acta, 1123, 156–162.
  • KAWASHIMA, H., KUSUNOSE, E., KIKUTA, Y., KINOSHITA, H., TANAKA, S., YAMAMOTO, S., KISHLMOTO T. and KUSUNOSE, M., 1994, Purification and cDNA cloning of human liver CYP4A fatty acid omega hydroxylase. Journal of Biochemistry (Tokyo), 116, 74–80.
  • KERR, B. M., THUMMEL, K. E., WURDEN, C. J., KLEIN, S. M., KROETZ, D. L., GONZALEZ, F. J. and LEVY, R. H., 1994, Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochemical Pharmacology, 47, 1969–1979.
  • KIKUTA, Y., KUSENOSE, E., ENDO, T., YAMAMOTO, S., SOGAWA, K., FUJII -KUROYAMA, Y. and KUSENOSE M., 1993, A novel form of cytochrome P-450 family 4 in human polymorphonuclear leukocytes. cDNA cloning and expression of leukotriene B4 co-hydroxylase. Journal of Biological Chemistry, 268, 9376–9380.
  • KIKUTA, Y., KUSENOSE, E., KONDO, T., YAMAMOTO, S., YAMAMOTO, S., KINOSHITA, H. and KUSENOSE M., 1994, Cloning and expression of a novel form of leukotriene B4 co-hydroxylase from human liver. FEBS Letters, 348, 70–74.
  • KIMURA, S., PASTEWKA J., GELBOIN, H. V. and GONZALEZ, F. J., 1987, cDNA and amino acid sequence of two members of the human P450IIC gene subfamily. Nucleic Acids Research, 15, 10053–10054.
  • KIMURA, H., SOGAWA, K., SAKAI, Y. and FUJII, K. Y., 1989, Alternative splicing mechanism in a cytochrome P-450 (P-450PB-1) gene generates the two mRNAs coding for proteins of different functions. Journal of Biological Chemistry, 264, 2338–2342.
  • KIMURA, S., UMENO, M., SKODA, R. C., MEYER, U. A. and GONZALEZ, F. J., 1989, The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and pseudogene. American Journal of Human Genetics, 45, 889–904.
  • KITADA, M., KAMATAKI, T., ITAHASHI, K., RIKIHISA, T. and KANAKUBO, Y., 1987, P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16a-hydroxylase of dehydro-epiandrosterone 3-sulfate. Journal of Biological Chemistry, 262, 13534–13537.
  • KLYOHARA, C., HIROHATA, T. and INUTSUKA, S., 1996, The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A gene. Japanese Journal of Cancer Research, 87, 18–24.
  • KLEINBLOESEM, C. H., VAN BRUMMELEN, P., FABER, H., DANHOF, M., VERMEULEN, N. P. E. and BREIIVIER, D. D., 1984, Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochemical Pharmacology, 33, 3721–3724.
  • KOBLE, K., 1993, Regional mapping of short tandem repeats on human chromosome 10: cytochrome P450 gene CYP2E, D105196, D105220 and D10S225. Genomics, 18, 702–704.
  • KOLARS, J. C., LOWN, K. S., SCHMIEDLIN -REN, P., GHOSH, M., FANG, C., WRIGHTON, S. A., MERION R. M. and WATIUNS, P. B., 1994, CY P3A gene expression in human gut epithelium. Pharmaco-genetics, 4, 247–259.
  • KOMORI, M., NISHIO, K., FUJITANI, T., OHI, H., KITADA, M., MIMA, S., UTAHASHI, K. and KAMATAKI T., 1989a, Isolation of a new human fetal liver cytochrome P450 cDNA clone: Evidence for expression of a limited number of forms of cytochrome P450 in human fetal livers. Archives of Biochemistry and Biophysics, 272, 219–225.
  • KOMORI, M., NISHIO, K., OHI, H., KITADA, M. and KAMATAKI, T., 1989b, Molecular cloning and sequence analysis of cDNA containing the entire coding region for human fetal liver cytochrome P-450. Journal of Biochemistry, 105, 161–163.
  • KOOP, D. R. and CASSAZZA, J. P., 1985, Identification of ethanol-inducible P-450 isozyme 3a as the acetone and acetal monooxygenase of rabbit microsomes. Journal of Biological Chemistry, 260, 13607–13612.
  • KOURI, R. E., MCKINNEY, C. E., SLOMIANY, D. J., SNOWGRASS, D. R., WRAY, N. P. and MCLEMORE T. L., 1982, Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analysed in cryopreserved lymphocytes. Cancer Research, 42, 5030–5037.
  • KRONBACH, T., FISCHER, V. and MEYER, U. A., 1988, Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics, 43, 630–635.
  • KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. and MEYER, U. A., 1989, Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 89–96.
  • KIJPFER, A. and BRANCH, R. A., 1985, Stereoselective mephobarbital hydroxylation coseggregates with mephenytoin hydroxylation. Clinical Pharmacology and Therapeutics, 38, 414–418.
  • KIJPFER, A. and PREISIG, R., 1984, Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. European Journal of Clinical Pharmacology, 26, 753–759.
  • KURTH, M. C. and KURTH, J. H., 1993, Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. American Journal of Human Genetics, 48, 166–168.
  • KUTT, H., WoLK, M., SCHERMAN, R. and McDOWELL, F., 1964, Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology, 14, 542–548.
  • LEE, K. D., BAEK, S. J. and SHEN, R. F., 1994, Cloning and characterization of the human thromboxane synthase gene promoter. Biochemical Biophysical Research Communications, 201, 379–387.
  • LEE, S. S. T., BUTERS, J. T. M., PINEAU, T., FERNANDEZ -SALGUERO, P. and GONZALEZ, F. J., 1996, Role of CYP2E1 in the hepatotoxicity of acetaminophen. Journal of Biological Chemistry, 271, 12063–12067 .
  • LEO, M. A., LASKER, J. M., RAUCY, J. L., KIM, C. L., BLACK, M. and LIEBER, C. S., 1989, Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. Archives of Biochemistry and Biophysics, 269, 305–312.
  • LIEHR, J. G., Ricci, M. J., JEFCOATE, C. R., HANNIGAN, E. V. and HOKANSON, J. A., 1995, 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes—implications for the mechanism of uterine tumorigenesis. Proceedings of the National Academy of Sciences, USA, 92, 9220–9224.
  • LINDBERG, R. L. P. and NEGISHI, M., 1989, Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino-acid residue. Nature, 339, 632–634.
  • Lou, Y. C., YING, L., BERTILSSON, L. and SJOQVIST, F., 1987, Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet, ii, 852–853.
  • LUCAS, D., MENEZ, C., GIRRE, C., BERTHOU, F., BODENEZ, P., JOANNET, I., HISPARD, E., BARDOU, L. G. and MENEZ, J. F., 1995, Cytochrome P4502E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics, 5, 298–304.
  • MAHGOUB, B. A., IDLE, J. A., DRING, L. G., LANCASTER, R. and SMITH, R. L., 1977, Polymorphic hydroxylation of debrisoquine in man. Lancet, 1, 584–586.
  • MAURICE, M., EMILIANI, S., DALET -BELUCHE I., DERANCOURT, J. and LANGE, R., 1991, Isolation and characterisation of a cytochrome P450 of the IIA subfamily from human liver microsomes. European Journal of Biochemistry, 200, 511–517.
  • McKAY, J. A., MELVIN, W. T., AHSEE, A. K., EWEN, S. W. B., GREENLEE, W. F., MARCUS C. B., BURKE, M. D. and MURRAY, G. I., 1995, Expression of cytochrome P450 in breast cancer. FEBS Letters, 374, 270–272.
  • McKINNIoNi, R. A., BURGESS, W. M., GONZALEZ, F. J., GASSER, R. and McMANus, M. E., 1994, Species-specific expression of CYP4B1 in rabbit and human gastrointestinal tissues. Pharmacogenetics, 4, 260–270.
  • McKINNIoN, R. A., HALL, P. D., QUATTROCHI, L. C., TuxEm, R. H. and McMANus, M. E., 1991, Localisation of CYP1A1 and CYP1A2 messanger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridisation. Hepatology, 14, 848–856.
  • MEEHAN, R. R., GOSDEN, J. R., ROUT, D., HASTIE, N. D., FRIEDBERG, T., ADESNIK, M., BUCKLAND, VAN HEYNINGEN V., FLETCHER, J., SPURR, N. K., SWEENEY, J. and WOLF, C. R., 1988, Human cytochrome P-450 PB-1: A multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. American Journal of Human Genetics, 42, 26–37.
  • MILES. J. S., BICKMORE W., BROOK, J. D., MCLAREN, A. W., MEEHAN, R. and WOLF, C. R., 1989a, Close linkage of the human cytochrome P450IIA and P450IIB gene subfamilies: implications for the assignment of substrate specificity. Nucleic Acids Research, 17, 2907–2917.
  • MILES, J. S., MCLAREN, A. W. and WOLF, C. R., 1989b, Alternative splicing in the human cytochrome P45IIB gene generates a high level of aberrant messages. Nucleic Acids Research, 17, 8241-8255. MILES, J. S., MCLAREN, A. W., FORRESTER, L. M., GLANCEY, M. G., LANG, M. A. and WOLF, C. R., 1990, Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochemical Journal, 267, 365–371.
  • MILES, J. S., MCLAREN, A. W., GONZALEZ, F. J. and WOLF, C. R., 1990b. Alternative splicing in the human cytochrome P450IIB6 gene: use of a cryptic exon within intron 3 and splice acceptor site within exon 4. Nucleic Acids Research, 18, 189.
  • MILES, J. S., SPURR, N. K., GOUGH, A. C., JOWETT, MCLAREN, A. W., BROOK, J. D. and WOLF, C. R., 1988, A novel human cytochrome P450 gene (P450IIB): Chromosomal localisation and evidence for alternative splicing. Nucleic Acids Research, 16, 5783–5795.
  • MIMURA, M., BABA, T., YAMAZAKI, H., OHMORI, S., INUI, Y., GONZALEZ, F. J., GUENGERICH, F. P. and SHIMADA, T., 1993, Characterisation of cytochrome P-450 2B6 in human liver microsomes. Drug Metabolism and Disposition, 21, 1048–1056.
  • MINERS, J. 0., REES, D. L. P., VALENTE, L., VERONESE, M. E. and BIRKETT, D. J., 1995, Human hepatic cytochrome P450 2C9 catalyzes the rate limiting pathway of Torsemide metabolism. Journal of Pharmacology and Experimental Therapeutics, 272, 1076–1081.
  • MOLOW, D. T., SCHEUTZ, E.G., WRIGHTON S. A., WATKINS, P. B., KREMERS, P., MENDEZ -PICON, G., PARKE, G. A. and GUZELIAN, P. S., 1986, Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. Proceedings of the National Academy of Sciences, USA, 83, 5311–5315.
  • MURRAY, G. I., PRITCHARD, S., MELVIN, W. T. and BURKE, M. D., 1995, Cytochrome P450 CYP3A5 in the human anterior pituitary gland. FEBS Letters, 364, 79–82.
  • NAKAMURA, K., GOTO, F., RAY, W. A., MCALLISTER, C. B., JAcQz, E., WILKINSON, G. R. and BRANCH, R. A., 1985, Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapeutics, 38, 402–408.
  • NHAMBURO, P. T., GONZALEZ, F. J., MCBRIDE, 0. W., GELBOIN, H. V. and KIMURA, S., 1989, Identification of a new P450 expressed in human lung: complete cDNA sequence, cDNA-directed expression and chromosome mapping. Biochemistry, 28, 8060–8066.
  • NHAMBURO, P. T., KIMURA, S., MCBRIDE, 0. W., KOZAK, C. A., GELBOIN, H. V. and GONZALEZ, F. J., 1990, The human CYP2F gene subfamily: identification of a cDNA encoding a new cytochrome P450, cDNA directed expression, and chromosome mapping. Biochemistry, 29, 5491–5400.
  • NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, 0., COON, M. J., ESTABROOK, R. W., GUNSALUS I. C. and NEBERT D. W., 1996, P450 superfamily : update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1–42.
  • OHASHI, K., RUAN, K., KULMACZ, R. J., Wu, K. J. and WANG, L., 1992, Primary structure of human thromboxane synthase determined from the cDNA sequence. Journal of Biological Chemistry, 267, 789–793.
  • OKINO, ST., QUATTROCHI, L. C., PENDURTH U. R., MCBRIDE, OW. and TUKEY, R. H., 1987, Characterisation of multiple human cytochrome P-450 1 cDNAs. Journal of Biological Chemistry, 262, 16072–16079.
  • PAGE, M. A., BOUTAGY, J. S. and SHENFIELD, G. M., 1991, A screening test for slow metabolisers of tolbutamide. British Journal of Clinical Pharmacology, 31, 649–654.
  • PALMER, C. N. A., RICHARDSON, T. H., GRIFFIN, K. J., Hsu, M. H., MUERHOFF, A. S., CLARK, J. E. and JOHNSON, E. F., 1993, Characterisation of a cDNA encoding a human kidney cytochrome P-450 fatty acid co-hydroxylase and the cognate enzyme expressed in Escherichia coli. Biochimica et Biophyska Acta, 1172, 161–166.
  • PELKONEN, 0., SOTAN1EMI, E. A. and AHOKAS, J. T., 1985, Coumarin 7-hydroxylase activity in human liver microsomes: properties of the enzyme and interspecies comparisons. British Journal of Clinical Pharmacology, 19, 59–66.
  • PEMBLE S., SCHROEDER, K. R., SPENCER, S. R., MEYER, D. J., HALL1ER, E., BOLT, H. M., KETTERER, B. and TAYLOR, J. B., 1994, Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterisation of a genetic polymorphism. Biochemical Journal, 300, 271–276.
  • PERNECKY, S. J., PIPER, W. N. and COON, M. J., 1994, Characterisation of 5' flanking region of rabbit CYP2E1 and 2E2 genes: apparent insulin-responsive sequences. In Proceedings of the 10th International Symposium on Microsomes & Drug Oxidations, Toronto, July 1994.
  • PERROT, N., NALPAS, B., YANG, C. S. and BEAUNE, P. H., 1989, Modulation of cytochrome P450 isozymes in human liver by ethanol and drug intake. European Journal of Clinical Investigation, 19, 549–555.
  • PERSSON, I., JOHANSSON, I., BERGLING, H., DAHL, M. L., SEIDEGARD, J., RYLANDER, R., RANNUG, A., HOGBERG, J. and INGELMAN -SUNDBERG, M., 1993, Genetic polymorphism of cytochrome P45011E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Letters, 319, 207–211.
  • PETERSEN, D. D., MCKINNEY, C. E., IKEYA, K. et al., 1991, Human CYP1A1 gene: coseggregation of the enzyme inducibility phenotype and an RFLP. American Journal of Human Genetics, 48, 720–725. PEYRONNEAU, M.-A., RENAUD, J.-P., JAOUEN, M., URBAN, P., CULLIN, C., POMPON, D. and MANSUY, D., 1993, Expression in yeast of three allelic cDNAs coding for human liver P-450 3A4. Different stabilities, binding properties and catalytic activities of the yeast-produced enzymes. European Journal of Biochemistry, 218, 355–361.
  • PHILLIPS, I. R., SHEPHARD, E. A., ASHWORTH, A. and RABIN, B. R., 1985, Isolation and sequence of a human cytochrome P-450 cDNA clone. Proceedings of the National Academy of Sciences, USA, 82, 983–987.
  • POLAND, A., GLOVER, E. and KENDE, A. S., 1976, Stereospecific, high affinity binding of 2,3,7,8-tetrachloro dibenzo-p-dioxin by hepatic cytosol. Journal of Biological Chemistry, 251, 4936–4946.
  • PONGRATZ, I., MASON, G. G. and POELLINGER, L., 1992, Dual roles of the 90-kDa heat shock protein hsp90 in modulating functional activities of the dioxin receptor. Journal of Biological Chemistry, 267, 13728–13734.
  • PONGRATZ, I., STROMSTEDT, P. E., MASON, G. G. and POELLINGER, L., 1991, Inhibition of the specific DNA binding activity of the dioxin receptor by phosphatase treatment. Journal of Biological Chemistry, 266, 16813–16817.
  • QUATTROCHI, L. C., OKINO, S. T., PENDURTHI U. R. and TUKEY, R. H., 1985, Cloning and isolation of human cytochrome P-450 cDNAs homologous to dioxin-inducible rabbit mRNAsencoding P-4504 and P-450-6. DNA, 4, 395–400.
  • RAHMAN, A., KORZEKWA, K. R., GROGAN, J., GONZALEZ, F. J. and HARRIS, J. W., 1994, Selective biotransformation of taxol to 6a-hydroxytaxol by human cytochrome P450 2C8. Cancer Research, 54, 5543–5546.
  • RAUNIO, H., PASANEN M., MAENPAA J., HAKKOLA, J. and PELKONEN, 0., 1995, Expression of extrahepatic cytochrome P450 in humans. In G. M. Pacifici and G. N. Fracchia (eds), Advances in Drug Metabolism in Man (Luxenbourg : European Commission), pp. 233–288.
  • RAUNIO, H., SYNGELMÁ:, T., PASANEN M., JUVONEN, R., HONKAKOSKI, P., KAIRALUOMA, M. A., SOTANIEMI, E., LANG, M. A. and PELKONEN, 0., 1988, Immunochemical and catalytic studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse. Biochemical Pharmacology, 37, 3889–3895.
  • RELLING, M. V., AOYAMA, T., GONZALEZ, F. J. and MEYER, U. A., 1990, Tolbutamide and mephenytoin hydroxylation of human cytochrome P450s in the CYP2C family. Journal of Pharmacology and Experimental Therapeutics, 252, 442–447.
  • RETTIE, A. E., KORZEKWA, K. R., KUNZE, K. L., LAWRENCE, R. F., EDDY, A. C., AOYAMA, T., GELBOIN H. V., GONZALEZ, F. J. and TRAGER, W. F., 1992, Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: A role for P-4502C9 in the etiology of (S)-warfarin drug interactions. Chemical Research and Toxicology, 5, 54–59.
  • REYES, H., REISZ -PORSZASZ, S. and HANKINSON, 0., 1992, Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science, 256, 1193–1195.
  • RICHARDSON, T. H., SCHENKMAN, J. B., TURCAN, R., GOLDFARB, P. S. and GIBSON, G. G., 1992, Molecular cloning of a cDNA for rat diabetes-inducible cytochrome P45ORLM—hormonal regulation and similarity to the cytochrome P450 2E1 gene. Xenobiotka, 22, 621–631.
  • ROBSON, R. A., MINERS, J. 0., MATTHEWS, A. P., STUPANS I., MELLER, D., MuMANus, M. E. and BIRKETT, D. J., 1988, Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. Biochemical Pharmacology, 37, 1651–1659.
  • ROMKES, R., FALETTO, M. B., BLAISDELL, J. A., RAUCY, J. L. and GOLDSTEIN, J. A., 1991, Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry, 30, 3247–3255.
  • RYBERG, D., KURE, E., LYSTAD, S., SKAUG, V., STANGELAND, L., MERCY, I., BORRESEN, A. L. and HAUGEN, A., 1994, p53 mutations in lung tumours: relationship to putative susceptibility markers for cancer. Cancer Research, 54, 1551–1555.
  • SCHEUTZ, J. D., BEACH, D. L. and GUZELIAN, P. S., 1994, Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics, 4, 11–20.
  • SCHEUTZ, J. D. and GUZELIAN, P. S., 1995, Isolation of CYP3A5P cDNA from human liver: a reflection of a novel cytochrome P-450 pseudogene. Biochimica et Biophysica Acta, 1261, 161–165.
  • SCHEUTZ, J. D., KAUMA, S. and GUZELIAN, P. S., 1993, Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. Journal of Clinical Investigation, 92, 1018–1024.
  • SCHEUTZ, J. D., MOLOWA, D. T. and GUZELIAN, P. S., 1989, Characterisation of cDNA encoding a new member of the glucocorticoid-responsive cytochrome P450 in human liver. Archives of Biochemistry and Biophysics, 274, 355–365.
  • SCHMIDT, J. V., Su, G. H. T., REDDY, J. K., SIMON, M. C. and BRADFIELD, C. A., 1996, Characterisation of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proceedings of the National Academy of Sciences, USA, 93, 6371–6376.
  • SCHWEIKL, H., TAYLOR, J. A., KITAREEWAN, S., LINKO, P., NAGORNEY, D. and GOLDSTEIN, J. A., 1993, Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics, 3, 239-249. SCOTT, J. and POFFENBARGER, P. L., 1979, Pharmacogenetics of Tolbutamide metabolism in humans. Diabetics, 28, 41–51.
  • SESARDIC, B., Booms, A. R., EDWARDS, R. J. and DAVIES, D. S., 1988, A form of cytochrome P450 in man orthologous to form d in the rat catalyses the 0-deethylation of phenacetin and is inducible by cigarette smoking. British Journal of Clinical Pharmacology, 26, 363–372.
  • SINDRUP S. H., BRoSEN, K., HANSEN, M. G. J., AAES-JORGENSEN, T., OVERO, K. F. and GRAM, L. F., 1993, Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Therapeutic Drug Monitoring, 13, 11–17.
  • SHAW, G. C. and FuLco, A. J., 1992, Barbiturate-mediated regulation of the cytochrome P450BM-s gene of Bacillus megaterium by Bm3R1 protein. Journal of Biological Chemistry, 267, 5515–5526.
  • SHIMADA, T., MARTIN, M. V., PRUESS -SCHWARTZ, D., MARNETT, L. J. and GUENGERICH, F. P., 1989, Roles of individual cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Research, 49, 6304–6312.
  • SHIMADA, T., MISONO, K. S. and GUENGERICH, F. P., 1986, Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterisation of two similar forms involved in the reaction. Journal of Biological Chemistry, 261, 909–921.
  • SMIMADA, T., YAMAZAKI, H., MIMURA M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variation in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
  • SMITH, C. A. D., GOUGH, A. C., LEIGH, P. N., SUMMERS, B. A., HARDING, A. G., MARANGANORE, D. M., STURMAN, S. G., SCHAPIRA, A. H. V., WILLIAMS, A. L., SPURR, N. K. and WOLF, C. R., 1992, Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet, 339, 1365–1372.
  • SMITH, G., HARRISON, D. J., EAST, N., RAE, F., WOLF, H. and WOLF, C. R., 1993, Regulation of cytochrome P450 gene expression in human colon and breast tumour xenografts. British Journal of Cancer, 68, 57–63.
  • SMITH, G., HENDERSON, C. J., PARKER, M. G., WHITE, R., BARS, R. G. and WOLF, C. R., 1993, 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene, an extremely potent modulator of mouse hepatic cytochrome P450 gene expression. Biochemical Journal, 289, 807–813.
  • SMITH, G., STANLEY, L. A., Sim, E., STRANGE, R. C. and WOLF, C. R., 1995, Metabolic polymorphisms and cancer susceptibility. Cancer Surveys, 25, 27–65.
  • SONG, B. J., GELBOIN, H. V., PARK, S. S., YANG, S. C. and GONZALEZ, F. J., 1986, Complementary DNA and protein sequences of ethanol-inducible rat and human cytochrome P-450s. Transcriptional and posttranscriptional regulation of the rat enzyme. Journal of Biological Chemistry, 261, 16689–16697.
  • SPINK, D. C., HAYES, C. L., YOUNG, N. R., CHRISTOU M., SUTTER, T. R., JEFCOATE, C. R. and GIERTHY J. F., 1994, The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in mcf-7 breast cancer cells—evidence for induction of a novel 17-beta-estradiol 4-hydroxylase. Journal of Steroid Biochemistry and Molecular Biology, 51, 251–258.
  • SPURR, N. K., GOUGH, A. C., SMITH, C. A. D. and WOLF, C. R., 1991, Genetic analysis of cytochrome P450 systems. Methods in Enzymology, 206, 149–173.
  • SPURR, N. K., GOUGH, A. C., STEVENSON, K. and WOLF, C. R., 1987, Msp-1 polymorphism detected with a cDNA probe for the P450 I family on chromosome 15. Nucleic Acids Research, 15, 5901. SPURR, N. K., GOUGH, A. C., STEVENSON, K. and WOLF, C. R., 1989, The human cytochrome P450 CYP3 locus: assignment to chromosome 7q22-qter. Human Genetics, 81, 171–174.
  • STEPHENS, E. A., TAYLOR, J. A., KAPLA N., YANG, C.-H., HSIEH, L. L., LUCIER, G. W. and BELL, D. A., 1994, Ethnic variation in the CYP2E1 gene: Polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics, 4, 185–192.
  • STUBBINS M. J., HARRIES, L. W., SMITH, G., TARBIT, M. H. and WOLF, C. R., 1996, Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetks, in press.
  • SUTTER, T. R., TANG, Y. M., HAYES, C. L., Wo, Y. Y. P., JABS, E. W., LI, X., YIN, H., CODY, C. W. and GREENLEE, W. F., 1994, Complete cDNA sequence of a human dioxin-inducible messenger RNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. Journal of Biological Chemistry, 269, 13092–13099.
  • TAIOLI, E., CROFTS, F., TRACHMAN J., BAYO, S., TONIOLO, P. and GARTE, S. J., 1995, Racial differences in CYP1A1 genotype and function. Toxicology Letters, 77, 357–362.
  • TSUNEOKA, Y., MATSU°, Y., OKUYAMA, E., WATANABE, Y. and ICHIKAWA, Y., 1996, Genetic analysis of the cytochrome P-450I1C18 (CYP2C18) gene and a novel member of the CYP2C subfamily. FEB S Letters, 384, 281–284.
  • TUCKER, G., 1994, Clinical implications of genetic polymorphism in drug metabolism. Journal of Pharmacy and Pharmacology, 46 (suppl. 1), 417–424.
  • TUCKER, G. T., SILAS, J. H., IYuN, A. 0., LENNARD, M. S. and SMITH, A. J., 1977, Polymorphic hydroxylation of debrisoquine. Lancet, i, 718.
  • UEMATSU, F., KIKUCHI, H., ABE, T., MOTOMIYA, K., OMATCHIT, SAGAMI, I. and WATANABE, M., 1991a, MspI polymorphism of the human CYP2E1 gene. Nucleic Acids Research, 19, 5797.
  • UEMATSU, F., KIKUCHI, H., MOTOMIYA, M., ABE, T., SAGAMI, I., OHMACHI, T., WAKUI, A., KANAMARU, R. and WATANABE, M., 1991b, Association between restriction fragment length polymorphism of the human CYP2E1 gene and susceptibility to lung cancer. Japanese journal of Cancer Research, 82, 254–256.
  • UIBO, R., AAVIK, E., PETERSON, P., PERHEENTUPA, J., ARANKO, S., PELKONEN, R. and KROHN, K. J., 1994, Autoantibodies to cytochrome P450 enzymes P450scc. P450c17 and P450c21 in autoimmune polyglandular disease types land II in isolated Addison's disease. journal of Clinical Endocrinology & Metabolism, 78, 323–328.
  • UMBENHAUER, D. R., MARTIN, M. V., LLOYD, R. S. and GUENGERICH, F. P., 1987, Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. Biochemistry, 26, 1094–1099.
  • VASKO, M. R., BL, R. D., DALY, D. D. and PIPPENGER CE., 1980, Inheritance of phenytoin hypometabolism : a kinetic study of one family. Clinical Pharmacology and Therapeutics, 27, 96–103.
  • VECCHINI, F., LENOIR -VIALE, M. C., CATHELINEAU, C., MAGDALOU, J., BERHARDT, B. A. and SHROOT, B., 1994, Presence of a retinoid responsive element in the promoter region of the human cytochrome P4501A1 gene. Biochemical Biophysical Research Communications, 201, 1205–1212.
  • VENEPALLY, P., CHEN, D. and KEMPER, B., 1992, Transcriptional regulatory elements for basal expression of cytochrome P450IIc genes. Journal of Biological Chemistry, 267, 17333–17338.
  • VERMELI, P., FERRARI, M. D., BURUMA, 0. J. S., VEENEMA, H. and DE WOLFF, F. A., 1988, Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family. Clinical Pharmacology and Therapeutics, 44, 588–593.
  • VERONESE, M. E., DOECKE, C. J., MACKENZIE, P. I., McMANus, M. E., MINERS, J. 0., Rs, D. L. P., GASSER, R., MEYER, U. A. and BIRKETT, D. J., 1993, Site-directed mutation studies of human liver cytochrome-P-450 isoenzymes in the CYP2C family. Biochemical Journal, 289, 533–538.
  • VERONESE, M. E., MACICENZIE, P. I., DOECKE, C. J., MCMANUS, M. E., MINERS, J. 0. and BIRKETT D. J., 1991, Tolbutamide and phenytoin hydroxylation by cDNA-expressed human liver cytochrome P4502C9. Biochemistry and Biophysics Research Communications, 175, 1112–1118.
  • WAKABAYASHI, K., NAGAOM ESUMI H. and SUGIMURA, T., 1992, Food derived mutagens and carcinogens. Cancer Research, 52, 2092–2098.
  • WANG, S.-L., HUANG, J., LAX, M.-D. and TSAI, J.-J., 1995, Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics, 5, 37–42.
  • WARD, S. A., GOTO, F., NAKAMURA, K., JAcQz, E., WILKINSON, G. R. and BRANCH, R. A., 1987, S-mephenytoin 4"-hydroxylase is inherited as an autosomal-recessive trait in Japanese families. Clinical Pharmacology and Therapeutics, 42, 96–99.
  • WARD, S. A., HELSBY, N. A., SICJELBO, E., BROSEN, K., GRAM, L. F. and BRECICENRIDGE, A. M., 1991, The activation of the biguanide antimalarial proguanil coseggregates with the mephenytoin oxidation polymorphism: a panel study. British Journal of Clinical Pharmacology, 31, 689–692.
  • WATANABE, J., HAYASHI, S.-I., NAKACHI, N., ImAI, K., SUDA, Y., SEKINE, T. and KAWAJIRI, K., 1990, PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Research, 18, 7194.
  • WEDLUND, P. J., ASLANIAN W. S., MCALLISTER, C. B., WILKINSON, G. R. and BRANCH, R. A., 1984, Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug polymorphism. Clinical Pharmacology and Therapeutics, 36, 773–780.
  • WHITE, P. C. and NEW, M. I., 1988, Molecular genetics of congenital adrenal hyperplasia. In Balliere's Clinical Endocrinology & Metabolism, vol. 2 no. 4, pp. 941–965.
  • WILKINSON, G. R., GUENGERICH, F. P. and BRANCH, R. A., 1989, Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacological Therapeutucs, 43, 53–76.
  • WINQVIST, 0., GUSTAFSSON, J., RORSMAN, F., KARLSSON, F. A. and KAMPE 0., 1993, Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type I and Addison's disease. Journal of Clinical Investigation, 92, 2377–2385.
  • WOLF, C. R., 1990, Metabolic factors in cancer susceptibility. Cancer Surveys, 9, 437–474.
  • WRIGHTON, S. A., BRIAN, W. R., SARI, M. A., IWASAKI, M., GUENGERICH, F. P., RAUCY, J. L., MOLOWA D. T. and VANDENBRANDEN, M., 1990, Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Molecular Pharmacology, 38, 207–13.
  • WRIGHTON, S. A., MAUREL, P., SCHEUTZ, E. G., WATKINS, P. B., YOUNG, B. and GUZELIAN, P. S., 1985, Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p. Biochemistry, 24, 2171–2178.
  • WRIGHTON, S. A., ThomAs, P. E., WILLIS, P., MAINES, S. L., WATKINS, P. B., LEVIN, W. and GUZELIAN P. S., 1987, Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats. journal of Clinical Investigation, 80, 1017–1022.
  • YAMANO, S., NAGATA, K., YAMAZOE, Y., KATO, R., GELBOIN, H. V. and GONZALEZ, F. J., 1989, cDNA and deduced amino acid sequence of human P450 IIA3 (CY P2A3). Nucleic Acids Research, 17, 4888.
  • YAMANO, S., NHAMBURO, P. T., AOYAMA, T., MEYER, U. A., INABA, T., KALOW W., GELBOIN, H. V.,
  • MCBRIDE, 0. W. and GONZALEZ, F. J., 1990b, cDNA cloning, sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the JIB mRNAs in human liver. Biochemistry, 28, 7340–7348.
  • YAMANO S., TATSUNO, J. and GONZALEZ, F. J., 1990a, The CYP2A3 gene product catalyses coumarin 7-hydroxylation in human liver microsomes. Biochemistry, 29, 1322–1329.
  • YANO M., FALVEY, E. and GONZALEZ, F. J., 1992, Role of the liver-enriched transcription factor DBP in expression of the cytochrome P450 CYP2C6 gene. Molecular Cell Biology, 12, 2847–2854.
  • YASUMORI, T., KAWANO S., NAGATA, K., SHIMADA M., YAMAZOE, Y. and KATO, R., 1987, Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form. Journal of Biochemistry, 102, 1075–1082.
  • YUN, C. H., SHIMADA, T. and GUENGERICH, F. P., 1991, Purification and characterisation of human liver microsomal cytochrome P-450-2A6. Molecular Pharmacology, 40, 679–685.
  • Yu, C.-H., SHIMADA, T. and GUENGERICH, F. P., 1992, Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. Cancer Research, 52, 1868–1874.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.